Artivion (AORT) Truist Securities MedTech Conference 2026 summary

Portfolio evolution and market opportunities

• Expanded from aortic focus to comprehensive aortic arch portfolio through four acquisitions, including On-X, Jotec, Ascyrus Medical (AMDS), and Endospan (NEXUS).

• U.S. aortic arch market opportunity estimated at $400 million, with AMDS and NEXUS as primary drivers; global stent graft portfolio could reach $2 billion if fully approved.

• Mechanical valve market expected to expand from $250 million to $400 million globally due to recent data.

Product launches and commercialization strategies

• AMDS launched under HDE in Q1 last year, targeting 6,000 procedures and a $150 million U.S. market; PMA approval expected soon to expand addressable market.

• Early AMDS adoption in 120 of 800 U.S. centers, with focus on overcoming IRB and starter set hurdles; PMA expected to accelerate adoption.

• NEXUS acquisition completed in May; U.S. launch planned for January 2027, with inventory build, rep hiring, and surgeon training underway.

Market dynamics and growth drivers

• NEXUS targets a $150 million U.S. market with strong customer demand and minimal standard of care alternatives; launch expected to be rapid due to concentrated customer base.

• Arcevo (frozen elephant trunk) in clinical trials, targeting 20% of acute Type A market and chronic dissection reoperations; market entry expected in early 2029.

• Synergies across portfolio enable strong pull-through and customer access, leveraging relationships with cardiac and vascular surgeons.